1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,923 | 0,935 | 12:45 | |
| 0,922 | 0,940 | 12:44 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:00 | SynAct Pharma AB: Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering | 81 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, reported today that resomelagon in combination... ► Artikel lesen | |
| Fr | SynAct Pharma AB: SynAct obtains key US patent for resomelagon securing exclusivity until 2044 | 177 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the United States Patent and Trademark Office (USPTO) have provided the issue notification of US patent 12,661,336 with issue date 23 June 2026... ► Artikel lesen | |
| Do | SynAct Pharma AB: Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) | 208 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) held its Annual General Meeting today, Thursday 11 June 2026, at the offices of MAQS Advokatbyrå in Stockholm. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman... ► Artikel lesen | |
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.05. | SynAct Pharma AB: SynAct Pharma publishes Q1 2026 interim results | 181 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2026.
"As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous... ► Artikel lesen | |
| 06.05. | SynAct Pharma AB: SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study | 389 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully completed dosing... ► Artikel lesen | |
| 26.03. | SynAct Pharma AB: SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon | 220 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the first patients were dosed... ► Artikel lesen | |
| 03.03. | SynAct Pharma - Multiple shots on goal in 2026 for resomelagon | 399 | Edison Investment Research | SynAct Pharma's FY25 results reflect a year of solid execution, highlighted by the continued advancement of lead asset resomelagon in the Phase IIb ADVANCE trial in rheumatoid arthritis (RA). With enrolment... ► Artikel lesen | |
| 24.02. | SynAct Pharma AB: SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer | 177 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Ann Kristin... ► Artikel lesen | |
| 18.02. | SynAct Pharma AB: SynAct Pharma Year-end Report 2025 | 186 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced its Year-end Report 2025
"As we close the fourth quarter and conclude 2025, I am pleased with the steady progress SynAct Pharma has made across clinical... ► Artikel lesen | |
| 10.02. | SynAct Pharma - Resomelagon progresses in RA, viral infections | 449 | Edison Investment Research | SynAct Pharma has completed patient recruitment for its Phase IIb ADVANCE trial (n=240) in rheumatoid arthritis (RA), while initiating the Phase II RESPIRE study in hospitalised with respiratory insufficiency... ► Artikel lesen | |
| 06.02. | SynAct Pharma AB: SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study | 401 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has successfully reached the recruitment... ► Artikel lesen | |
| 30.01. | SynAct Pharma AB: SynAct Pharma initiates Phase 2 study in respiratory insufficiency | 362 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that it has initiated... ► Artikel lesen | |
| 19.01. | SynAct Pharma AB: SynAct Pharma appoints Malin Wikstrand as interim CFO | 214 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announces that Malin Wikstrand... ► Artikel lesen | |
| 27.11.25 | SynAct Pharma AB: Report from the Extraordinary General Meeting of SynAct Pharma AB | 276 | GlobeNewswire (Europe) | An Extraordinary General Meeting in SynAct Pharma AB (publ) was held today, 27 November 2025, at MAQS Advokatbyrå's premises at Stureplan 19 in Stockholm. Chairperson of the General Meeting was Matilda... ► Artikel lesen | |
| 03.11.25 | SynAct Pharma AB: Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion | 311 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, has randomized 190 out of 240 patients... ► Artikel lesen | |
| 31.10.25 | SynAct Pharma - Approaching a catalyst-rich period | 402 | Edison Investment Research | SynAct Pharma's Q325 results underscored the company's steady progress on its clinical strategy, led by the ongoing Phase IIb ADVANCE trial evaluating resomelagon as a first-line treatment for rheumatoid... ► Artikel lesen | |
| 30.10.25 | SynAct Pharma AB: SynAct Pharma publishes Q3 2025 interim results | 221 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the third quarter 2025.
"SynAct is in a fortunate position now as the company has two development tracks, across both autoimmune... ► Artikel lesen | |
| 28.10.25 | SynAct Pharma - Differentiated inflammation resolution approach | 363 | Edison Investment Research | SynAct Pharma is focused on inflammation resolution therapeutics. Its lead asset, resomelagon, is differentiated by its novel mechanism, targeting specific melanocortin receptor subtypes believed to... ► Artikel lesen | |
| 16.09.25 | SynAct Pharma AB: SynAct Pharma's CFO Björn Westberg leaves for new leading position | 212 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution therapy, today announced that the company's... ► Artikel lesen | |
| 05.09.25 | SynAct Pharma AB: SynAct appoints Mads Bjerregaard as Chief Business Officer | 256 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced the appointment of Mads... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 36,310 | +1,45 % | Iran-Krieg: DAX schwächer, Öl höher, Asien tiefrot - Apple, BASF, Infineon, Bayer, Porsche ... | Der DAX hat am Freitag weitere Verluste hinnehmen müssen. Der deutsche Leitindex verlor 0,8 Prozent auf 24.759,05 Punkte. Auf Wochensicht summierten sich die Verluste sogar auf 1,4 Prozent. Und auch... ► Artikel lesen | |
| MERCK KGAA | 133,70 | -1,26 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 60,93 | -0,03 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,380 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| NOVO NORDISK | 38,320 | +1,86 % | Eli Lillys neues Abnehmmittel könnte Ozempic alt aussehen lassen | Eli Lilly hat auf dem größten Diabeteskongress der Welt Daten präsentiert, die die Adipositas-Pipeline des Konzerns in einem völlig neuen Licht erscheinen lassen. Auf dem Jahreskongress der American... ► Artikel lesen | |
| ELI LILLY | 978,30 | -0,08 % | Check: Pharma-Aktien: Nvidia-Chef: KUI-Kaufgelegenheit - Eli Lilly: Studiendaten - Porsche: Kaufen | Für Jensen Huang ist der Abverkauf der KI-Aktien kein Grund sich Sorgen zu machen. Für ihn steht die KI-Revolution erst am Anfang. Sein Tipp: "Anleger sollten sich freuen, sie können günstig kaufen".... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,175 | +0,12 % | Aquestive Therapeutics, Inc. - 8-K, Current Report | ||
| GILEAD SCIENCES | 108,40 | -0,11 % | Nabelschnurzellen aus Dresden bringen neuen Schwung in die Zelltherapie-Debatte. | ||
| ETON PHARMACEUTICALS | 31,550 | -0,13 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| PFIZER | 22,555 | -0,38 % | Dividenden-Liebling Pfizer: Absage an Merz | Der US-amerikanische Pharma-Riese Pfizer hat große Investitionspläne für Deutschland. Doch diese stehen nun offenbar auf dem Prüfstand. Der Grund dafür sind die geplanten härteren Sparvorgaben in der... ► Artikel lesen | |
| ASPIRE BIOPHARMA | 5,180 | +4,44 % | Aspire Biopharma Holdings, Inc.: Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue | Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systemsAcquisition significantly accelerates Aspire's revenue, earnings growth... ► Artikel lesen | |
| NOVARTIS | 132,68 | +0,30 % | Novartis klebt sich nochmal eine Kooperation | ||
| ATRIUM THERAPEUTICS | 12,370 | 0,00 % | Atrium Therapeutics Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,290 | +0,07 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| LB PHARMACEUTICALS | 28,390 | -0,11 % | LB PHARMACEUTICALS INC - 8-K, Current Report |
Das Unternehmen SYNACT PHARMA AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,162 (-12,56 %) liegt der Kurs bei 1,128 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.